Mesoblast Ltd Received its Third Buy in a Row, page-7

Cosair the LVAD interim results are likely in Q3 2018, hopefully it will still be Q3 when they are published. SI announced this at the last webinar, might have been during the Q and A. It sounded rather like if MSB were the funding the trial rather than the NIH they may have been announced when available.

Mark Breidenbach from Oppenheimer wrote;

Instead, trial investigators have opted against data unblinding before a 12-month analysis of secondary endpoints in 3Q18.

http://www.markets.co/mesoblast-ltd-receives-a-buy-from-oppenheimer/143136/